[1] ICRU, Report 44. Tissue substitutes in radiation dosimetry and measurement. Report 44 Bethesda, MD20814: ICRU Publications, ( 1989).
[2] M. Ghiassi-Nejad, M. Jafarizadeh, M.R. Ahmadian-Pour , A.R. Ghahramani. Dosimetric characteristics of 192Ir sources used in interstitial brachytherapy, Applied Radiation and Isotope , 55 (2001) 189–195.
[3] V. Lohrabian, S. Sheibani, M.R. Aghamiri, B. Ghozati, H. Pourbeigi, H.R. Baghani. Determination of Dosimetric Characteristics of IrSeed 125I BrachytherapySource, Iranian Journal of Med Phys, 10(3) (2013) 109–117.
[4] A.S. Meigooni, M.M. Yoe-Sein, A.Y. Al-Otoom, K.T. Sowards. Determination of the Dosimetric characteristics of InterSource125Iodine brachytherapy source, Applied Radiation and Isotope, 56 (2002) 589–599.
[5] A.S. Meigooni, V. Misha, H. Panth, J.F. Williamson. Instrumentation and dosimeter-size artifacts in quantitative thermoluminescentdosimetry of low-dose field, Med Phys, 22 (1995) 555–561.
[6] R. Nath, L.L. Anderson, G. Luxton, K.A. Weaver, J.F. Williamson, A.S. Meigooni. Dosimetry of interstitial brachytherapy source: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43, Med Phys, 22 (1995) 209–234.
[7] V. Lohrabian, S. Sheibani, M.R. Aghamiri, B. Ghozati, H. Pourbeigi, M. Havasian. Determination ofdosimetric parameters of new brachytherapy seed (125IrSeed) using EBT radiochomic film and TL dosimeters, Journal of Ilam University of Medical Sciences 21(1) (2013) 78–88.
[8] M.J. Rivard, B.M. Coursey, L.A. DeWerd, W.F. Hanson, M. SaifulHuq, G.S. Ibbott, M.G. Mitch, R. Nath, J.F. Williamson. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations, Med Phys, 31 (2004) 633–674.
[9] G. Raisali, F. MokhlesGerami, R. Khodadadi, B. Piroozfar. Determination of dosimetry parameters for low energy brachytherapy sources based upon TG-43U1 protocol using different MCNP tallies, J Nuclear Science and technology, 35 (2006) 29–36.
[10] T.D. Solberg, J.J. DeMarco, G. Hugo, R.E. Wallace. Dosimetric parameters of three new solid core I-125 brachytherapy source, Med Phys, 3(2) (2004) 119–134.
[11] R.E. Wallace, J.J. Fan. Report on the dosimetry of a new design 125I brachytherapy source, Med Phys, 26(9) (1999) 1925–1931.
[12] J.F. Williamson. Comparison of measured and calculated dose rates in water near 125I and 192Ir seeds, Med Phys, 18(4) (1991) 776-785.
[13] J.F. Williamson, A.S. Meigooni. Quantitative dosimetry methods in brachytherapy: in brachytherapy physics, edited by Williamson JF, Nath R, and Thomadsen R, Med Phys, (1995) 87.
[14] J.F. Williamson. Comparison of measured and calculated dose rates in water near 125I and 192Ir seeds, Med. Phys, 18 (1991) 776.
[15] J.F. Williamson. Comparison of measured and calculated dose rates in water near I-125 and Ir-192 seeds, Med Phys, 18(4) (1991) 776–86.
[16] M.J. Zelefsky, W.F. Whitmore. Long-term results of retropubic permanent 125Iodine implantation of prostate for clinically localized prostatic cancer, J. Urol. (Paris), 158 (1997) 23–30.
[17] H.R. Baghani, V. Lohrabian, M.R. Aghamiri, M. Robatjazi. Monte Carlo Determination of Dosimetric Parameters of a new 125I brachytherapy source According to AAPM TG-43U1 protocol, Archives of Iranian Medicine, 19(3) (2016) 186–91.
[18] K. Weaver, V. Smith, D. Huang, C. Barnett, M. Schell, C. Ling. Dose parameters of 125I and 192Ir seeds, Med. Phys, 16 (1989) 636.